Breathe BioMedical Inc. is a medical technology company. It is focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Breath analytics involves the collection, processing, and analysis of breath samples to identify biomarker patterns associated with specific diseases. It is developing a proprietary end-to-end breath analytics platform, the intended use of which is to enable breath testing for the detection of disease. Its platform technology combines three advanced technologies to sample, digitize and analyze breath with the potential to detect multiple diseases. Its spectrometer technology uses Cavity Ring-Down Spectroscopy (CRDS) to measure the volatile organic compounds (VOCs) in breath samples which are collected using its breath sampler device (SohnoXB). Spectrometer is designed to be very fast, permitting sample analysis down to parts-per-trillion levels.
企業コードBRTH
会社名Breathe BioMedical Inc
上場日- -
最高経営責任者「CEO」Dawes (William)
従業員数- -
証券種類Ordinary Share
決算期末- -
本社所在地191 Halifax Street
都市MONCTON
証券取引所NASDAQ OMX - NASDAQ BASIC
国Canada
郵便番号E1C 9R7
電話番号19024148148
ウェブサイトhttps://breathebiomedical.com/
企業コードBRTH
上場日- -
最高経営責任者「CEO」Dawes (William)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし